Robert Michael: Thank you, Liz. Good morning, everyone, and thank you for joining us. Our fourth quarter performance closes out another excellent year for AbbVie, and I am very pleased with the ...

AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA’s decline. ABBV’s Q4 2025 saw 18% Immunology growth and 10 ...

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie, Inc. (ABBV) initiated its adjusted earnings guidance for the full-year 2026, above ...

In this article: LLY Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound. Q4 2025EPS increased by 51% to $7.39 on a reported basis and increased by 42% ...

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the stocks with the lowest forward PE ratios. Leerink Partners boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $60 from $54 ...

Police discovered the bodies after a foul smell emanated from the locked room, which had been booked for three days. IMAGE: Kindly note that this image has been posted for representational purposes ...

New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.

a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates. Intangible asset impairment reflects a partial after-tax impairment charge ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus.

Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a ...

A discussion of the non-GAAP financial measures is included below under "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)." Fourth-Quarter Reported Results In Q4 ...

AbbVie Inc. (ABBV) reported better-than-expected earnings for the fourth quarter of 2025, with an EPS of $2.71, surpassing the forecast of $2.65. The company’s revenue also exceeded expectations, ...